US20160143982A1 - CURCUMA MANGGA VAl ET ZIPP EXTRACT AS A TREATMENT TO OVERCOME PROSTATE PROBLEMS - Google Patents

CURCUMA MANGGA VAl ET ZIPP EXTRACT AS A TREATMENT TO OVERCOME PROSTATE PROBLEMS Download PDF

Info

Publication number
US20160143982A1
US20160143982A1 US14/894,615 US201414894615A US2016143982A1 US 20160143982 A1 US20160143982 A1 US 20160143982A1 US 201414894615 A US201414894615 A US 201414894615A US 2016143982 A1 US2016143982 A1 US 2016143982A1
Authority
US
United States
Prior art keywords
extract
zipp
fraction
curcuma mangga
mangga val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/894,615
Other languages
English (en)
Inventor
Asep Aripin
Agung Heru KARSONO
Olivia Mayasari
Prika HARDADI
James M. AMBELA
James M. Sinambela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dexa Medica PT
Original Assignee
Dexa Medica PT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dexa Medica PT filed Critical Dexa Medica PT
Assigned to PT DEXA MEDICA reassignment PT DEXA MEDICA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARIPIN, ASEP, HARDADI, Priska, KARSONO, Agung Heru, MAYASARI, OLIVIA, SINAMBELA, JAMES M, TJANDRAWINATA, RAYMOND R
Publication of US20160143982A1 publication Critical patent/US20160143982A1/en
Priority to US15/984,529 priority Critical patent/US10688146B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A23L1/3002—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Definitions

  • the present invention relates to the herbal extract from Curcuma mangga Val et. Zipp. plant, including the extraction method and the description of biological activity of the extract, which show its ability to overcome the problem of prostate enlargement.
  • Prostate is a small gland only found in men and forms a part of the reproduction system. The role of the gland is in the forming of semen, namely sperm carrier fluid. Prostate gland is generally grows with age. However, the development of prostate gland can become a problem when it becomes sufficiently large to suppress the urethra. Benign Prostatic Hyperplasia (BPH) is a term for prostate growth which causes problems (Guess 2001: 152).
  • BPH occurs in men over 40 years old.
  • the enlargement of prostate results in the obstruction of the urethra, thus the process of urine excretion becomes disrupted and slower, and frequently becomes difficult to urinate. If left untreated, it will result in the emergence of urinary tract infection and kidney damage.
  • the enlargement will begin to occur at epithelial and stromal tissues in the prostate gland.
  • the enlargement of prostate gland is caused by abnormal changes in the process of cell growth. If the disease is not treated properly, it will increase the risk of prostate cancer (Guess 2001: 152; Beckman et al. 2005: 1356; Fine & Ginsberg 2008: 333).
  • prostate cancer is the second leading cause of death from cancer in the United States (Talcot et al. 2011: 1046; Fei Ye et al. 2007: 100). According to Winter et. al. (2001: 1227), the possibility of developing prostate cancer among men is one in 55 men aging 40-59 years and one in six men aging 60-79 years. Therefore, early treatment is necessary to prevent prostate cancer from getting worse.
  • Treatment of the enlargement of prostate gland that has grown into prostate cancer should be conducted by adjusting the treatment with the stage of the prostate cancer.
  • Prostatectomy or radiotherapy can be done to treat low risk prostate cancer.
  • a combination of low risk medication and adjuvant androgen suppressive can be used as a treatment (Sanda & Kaplan 2009: 2141).
  • the present invention is indicated for treatment of prostate cancer as well. Therefore, our present invention is expected to minimize the treatment by surgery or chemotherapy.
  • Curcuma mangga Val. et Zipp. with the local name temu mangga, is a family of Zingiberaceae, and known as one of the spices and native medicinal plants from Southeast Asia. The plants then spread to Indonesia, Indo-Malaysia, Australia, and even Africa. Almost every Indonesian and Asian has ever consumed the spice plant, mainly as seasoning. Surprisingly the inventors of the present invention found that the extract of Curcuma mangga Val. et Zipp. can be used to treat prostate problems. Prior to this invention, there has not been any study describing the use or the benefit of Curcuma mangga Val. et Zipp. extract to overcome prostate problems, including prostate enlargement, as described in the present invention.
  • the object of this invention is to disclose the potential use of natural ingredients to enrich the concept or theory that support the development of sciences, especially in health area. Moreover, it can provide a useful option, both in terms of preparation and processing practice of preparing a dosage form that is more practical in the use of Curcuma mangga Val. et Zipp. in health area, especially in treating prostate enlargement, by the extraction of the bioactive fractions.
  • the first aspect of the present invention is directed to a preparation containing Curcuma mangga Val. et Zipp. extract or fractions or compounds derived thereof, as a single active ingredient or in a combination, in an amount or effective dosage for prevention, treatment or therapy of prostate enlargement.
  • the preparations containing Curcuma mangga Val. et Zipp. extract that referred to the first aspect in the present invention could be used for prostate cancer therapy.
  • the preparations according to the present invention also contain excipient or additive substances that are pharmaceutically acceptable and physiologically feasible.
  • Second aspect of the present invention is directed to preparations containing Curcuma mangga Val. et Zipp. extract which functions as an inhibitor of the formation of 5-alpha-reductase enzyme.
  • Third aspect of the present invention is directed to preparations containing Curcuma mangga Val. et Zipp. extract which functions as an inhibitor of the formation of androgen receptor.
  • FIG. 1 shows Thin Layer Chromatography (TLC) profile of Curcuma mangga Val. et Zipp. extract.
  • FIG. 1A Observations at 254 nm UV light
  • FIG. 1B Observations at 366 nm UV light
  • FIG. 1C Observations at visible light
  • FIG. 1D Observations at 366 nm UV light after sprayed with H 2 SO 4 10%
  • FIG. 1E Observations at visible light after sprayed with H 2 SO 4 10%
  • FIG. 2 shows the effect of Curcuma mangga Val. et Zipp. extract against PC3 cells proliferation.
  • FIG. 3 shows the effect of Curcuma mangga Val. et Zipp. extract against A549 cells proliferation.
  • FIG. 4 shows result of FACS experiment a.) Control treatment b.) Treatment with extract of Curcuma mangga Val. et Zipp. 50 ⁇ g/ml c.) Treatment with extract of Curcuma mangga Val. et Zipp. 100 ⁇ g/ml d.) Treatment with extract of Curcuma mangga Val. et Zipp. 150 ⁇ g/ml.
  • FIG. 5 shows qPCR results of 5-alpha-reductase-1 genes in PC3 cells after the administration of Curcuma mangga Val. et Zipp. extract.
  • FIG. 6 shows qPCR results of androgen receptor genes in PC3 cells after the administration of Curcuma mangga Val. et Zipp. extract.
  • FIG. 7 shows qPCR results of PI3 Kinase genes in PC3 cells after the administration of Curcuma mangga Val. et Zipp. extract.
  • FIG. 8 shows Western Blot results of 5-alpha-reductase-1 in PC3 cells after the administration of Curcuma mangga Val. et Zipp. extract.
  • FIG. 9 shows Western Blot results of Dihydrotestosterone (DHT) in PC3 cells after the administration of Curcuma mangga Val. et Zipp. extract.
  • DHT Dihydrotestosterone
  • FIG. 10 shows the effect of Curcuma mangga Val. et Zipp. extract against the levels of DHT.
  • FIG. 11 shows the results of Curcuma mangga Val. et Zipp. extract administration to rats that had experienced prostate gland enlargement.
  • Rats from positive control group Rats from positive control group (Finasteride 1 mg/kg body weight)
  • FIG. 12 shows graphic of the percentage of seminal vesicle weight development of rats as experimental animals.
  • FIG. 13 shows graphic of DHT plasma concentrations (pg/mL) of each experimental animal groups.
  • FIG. 14 shows graphic of LH plasma concentrations (pg/mL) of each experimental animals group.
  • Table 1 shows the decreasing fold of genes expressions associated with DHT pathways.
  • Table 2 shows the decreasing fold of genes expressions associated with PI3/Akt and MAPK pathways.
  • Table 3 shows genes that experienced the highest increase of genes expressions.
  • Table 4 shows genes that experienced the lowest decrease of genes expressions.
  • the present invention teaches an extraction process of Curcuma mangga Val. et Zipp. resulting in an extract that has utility in treating prostate gland enlargement.
  • Curcuma mangga Val. et Zipp. is usually cultivated on the lowland up to altitude of 1000 m above sea level (Gusmaini et. al., 2004). Plants with the purpose as an anti-prostatic hyperplasia in accordance with the present invention were harvested between 8-12 months, when the parts of the plants above the soil have begun to turn yellow and dry out.
  • rhizome most preferred part of the plant of Curcuma mangga Val. et Zipp. is the rhizome.
  • the research of rhizomes were conducted on the basis that the secondary metabolites that have bioactivity, more commonly found in the rhizome, while the other parts of the plants at the harvest time were considered as waste.
  • the other parts of the plant should not be ruled out from the possibilities that they have the bioactivity that can be observed as well in the future.
  • the rhizome for raw materials are cleaned up first, the roots, the base and impurities are removed, and subsequently the raw materials are washed with water and drained. Thereafter, raw materials are air-dried and chopped to the length of 3-7 mm, and dried to obtain water content 13%.
  • the length of chopped raw materials is selected to such an extent to obtain optimal extraction results. If the slice is too small, it will contain fine particles that can impede the filtering process. Meanwhile, if the slice is too big, it could disrupt the dissolution of constituent(s) from inside matrix of raw materials. Certain length of raw materials needs to be determined in order to expand the surface area, thus the contact area during the extraction process becomes wider and more effective in extracting bioactive constituent(s) contained in the raw materials.
  • the materials are weighted and placed in an extractor, followed by maceration process and/or percolation using organic solvent(s) with ratio of (1:6)-(1-10) w/v, for 30-240 minutes at a temperature range of 30°-50° C.
  • bioactive constituent(s) in Curcuma mangga Val. et Zipp. shows the properties of semi-polar and non-polar which is soluble in non-water organic solvents that are semi-polar to non-polar
  • organic solvent(s) in the present invention includes but not limited to methanol, ethanol, methylene chloride, chloroform, petroleum ether, and acetone.
  • Extraction process was continued with concentrating the micella through an evaporation process at a temperature range of 50°-60° C. and a pressure range between 175-875 mbar until a concentrate is formed.
  • the concentrate obtained was added with fillers including betacyclodextrin, corn starch, and aerosil, and dried using an oven at a temperature range of 60°-70° C. for 24-48 hours, and the results were milled.
  • the yield of extract obtained in the present invention is about ⁇ 2-7%.
  • the following examples of extraction process are carried out.
  • the use of ethanol in the concentration of 70-96% and raw material/solvent ratio of (1:6)-(1:10) w/v, and the duration of maceration as well as percolation at specified temperature range, can optimally extract expected bioactive constituent(s) into micella liquid.
  • ethanol in the present invention is more advantageous, both from economic aspect, which covers production costs related to the duration of maceration and percolation, and from safety aspect of the workers and environment.
  • the extraction process is preferrably conducted at a temperature range of 30°-50° C. More preferably, the extraction process is done at temperature 50° C., because it produces higher yield. The use of temperature above 50° C. is not suggested due to the flammable nature of ethanol.
  • the extraction process could be conducted using ethanol at the concentration of 70-96%.
  • extraction using ethanol 70% is preferred because the extracted constituent in the production process is easier to be collected and not much residue left.
  • the optimal yield obtained using ethanol 70% is ⁇ 6.2%. This yield is higher, thus more economical, if compared with the yield obtained from extraction process using ethanol at the concentration above 70%.
  • the concentrate obtained through extraction process above was further given an equal amount of additional water, and liquid-liquid extraction was performed using organic solvent including hexane, ethyl acetate, chloroform, and dichloromethane. Subsequently, the water and organic phase was separated, followed by concentrating the organic phase through evaporation at low pressure until an extract concentrate was obtained.
  • filler addition is better to be conducted by mixing the filler suspension in the water first, approximately at the equal volume with the micella. Furthermore, filler suspension is added to the extract concentrate and homogenized by re-circulated and re-concentrated until 30-50% of the original volume was reached. The step of mixing the filler on the process of concentrating the extract is better, because the addition of filler can trap the active components that are non-polar, thus the adhesions of the active components to the machine could be reduced.
  • the fillers which are added into the concentrate includes betacyclodextrin, corn starch, and aerosil.
  • betacyclodextrin as a filler is because its molecule is shaped like a “basket” that has a polar and non-polar properties, thus it can “wrap” the non-polar components from Curcuma mangga Val. et Zipp constituents.
  • the porous nature of aerosil which can absorb non-polar components of the essential oils (which are thought to contain the bioactive components) into the pores, thus help to increase the capacity of main fillers of corn starch in drying the extract of Curcuma mangga Val. et Zipp.
  • the drying process is conducted for 24-48 hours to obtain the mass of dry extract.
  • the temperature is set in the range of 60°-70° C.
  • the temperature setting is made in such a way to preserve the active constituents and prevent the possibilities of alteration or damage of the active constituents in the extract caused by heat during the process. Further, the process is followed by grinding the dried extract.
  • Curcuma mangga Val. et Zipp that was obtained through the extraction process using methanol as the solvent has a bright yellow color with an aromatic odor and bitter taste. Meanwhile, Curcuma mangga Val. et Zipp that was obtained through the extraction process using ethanol as the solvent at the concentration of 70-96%, has a yellow to brownish yellow color with an aromatic odor and bitter taste. Methanolic extract is hardly soluble in water, whereas ethanolic extract is partly soluble in either water or ethanol. The percentages of loss on drying for both extracts were ⁇ 5.00%.
  • Phytochemical tests were conducted to check the content of secondary metabolites contained in the extract of Curcuma mangga Val. et Zipp. Phytochemical tests were conducted to reveal the presence of alkaloids, saponins, phenols, flavonoids, terpenoids, and steroids. Meanwhile, the test for terpenoids and steroids group was also performed by TLC.
  • Phytochemical test against saponin group was performed by weighing 500 mg of extract and given additional 10 ml of boiling water, shaken vigorously for 10 seconds, and then allowed to stand for 10 minutes. The solution was added with 1 drop of 2 N HCl and observed. Positive reaction against saponin test is occurred if foam appears and the foam persists after the addition of 2 N HCl. Curcuma mangga Val. et Zipp showed a positive reaction against saponin due to the foam that persists after the addition of 2 N HCl.
  • Flavonoid test was performed by weighing 500 mg of extracts, and then added with 10 ml of methanol and refluxed for 10 minutes. While still hot, the solution was filtered. The filtrate was diluted with 10 ml of water. Once cool, 5 ml of petroleum ether was added to the solution, and then the solution was shaken and allowed to stand. Methanol-water layer was collected and dried using an evaporator. The rest of dried extract was dissolved using 5 ml ethyl acetate and filtered. Furthermore, as many as 1 ml of the filtrate was taken, inserted into a test tube, and evaporated again until dry.
  • Phenol test was performed by weighing 500 g of extract and the extract was inserted into a test tube and then 20 ml of water was added to the tube and boiled. The solution was filtered while it was still hot, and the filtrate was taken and dropped into watch glass. Furthermore, several drops of iron (III) chloride solution was added to the filtrate and if it formed a dark green, blue, and/or purple solution, then it showed a positive reaction against phenol. From the results of this test, the extract of Curcuma mangga Val. et Zipp was stated positive against phenols test due to the formation of green solution.
  • Terpenoids and steroids test was performed by weighing 500 mg of extract and dissolved in 2 ml of chloroform, and then filtered. The resulting filtrate was subsequently transferred into a drop plate and allowed to stand until the solvent evaporated. Thereafter, Liebermann-Burchard reagent was added (1 drop of concentrated sulfuric acid and 3 drops of acetic acid anhydrate). If red, pink, and/or purple colors appeared, then it showed a positive reaction against terpenoid and or steroid. A positive result was showed by the terpenoid and steroid tests against Curcuma mangga Val. et Zipp extract by the onset of red color.
  • FIG. 1A is the result of the plate observation under 254 nm UV light, it showed a positive spots at Rf 0.20, 0.29, and 0.80. Observation under 366 nm UV light as in FIG.
  • FIG. 1B shows the fluorescent blue spot at Rf ⁇ 0.26, 0.34, and 0.42, as well as blue spot at Rf ⁇ 0.53.
  • FIG. 1C is the result of plate observation under visible light which showed no spots.
  • the TLC plates were further sprayed with 10% of H 2 SO 4 in the water, and then heated at temperature 150° C., and was observed under 366 nm UV light, light brown spot appeared at Rf ⁇ 0.29, blue spots at Rf ⁇ 0.47 and 0.83, and yellow spot at Rf ⁇ 0.91 ( FIG. 1D ). Meanwhile, when the plates were observed under visible light, brownish purple spots at Rf ⁇ 0.31 and light brown spot at Rf ⁇ 0.60 appeared, which showed a positive reaction against terpenoid and steroid ( FIG. 1E ).
  • the extract showed a positive reaction against flavonoids, saponins, phenols, terpenoids, and steroids, but showed a negative reaction against alkaloids. Meanwhile, the results of TLC analysis also showed that the extract of Curcuma mangga Val. et Zipp contains steroids and terpenoids.
  • Prostate cells used in the present invention are human prostate cancer cells (PC3).
  • human lung cancer (A549) cells were also being used as an additional supporting data of cell viability.
  • Cells were cultured using serum-containing medium in an incubator with temperature of 37° C. and CO2 at the concentration of 5% until 80% of surface of flask covered by cells. Further, cells were transferred into 96 well-plates using a medium without serum, and were incubated with the same conditions for 24 hours.
  • the treatment in the form of extracts of Curcuma mangga Val. et Zipp. with concentrations ranging from 25 ⁇ g/ml to 200 ⁇ g/ml was given to the cells and further re-incubated with similar conditions for 24 hours.
  • These cells culture method were applicable to all tests related to the inhibitory activity of Curcuma mangga Val. et Zipp. extract against the formation of enzyme 5-alpha-reductase-1 and androgen receptor, as well as microarray analysis.
  • IC50 the values that can shows the concentration of a sample required to induce 50% cell death from the whole population
  • A549 cells were also carried out on lung cancer (A549) cells as an additional data about Curcuma mangga Val. et Zipp activities against cells growth inhibition.
  • the performed method on A549 cells was similar to PC3 cells method.
  • cells were fixated prior to analyzing by FACS machine.
  • the cells fixation was performed by cell-washing process using phosphate buffer saline (PBS) and precipitation of the materials contained in the treatment medium.
  • PBS phosphate buffer saline
  • Cells and precipitated materials were incubated in 70% ethanol 70% at temperature of 4° C. for 24 hours.
  • cells were colored using propidium iodide and analyzed using FACS BD machine.
  • the result of MTT test showed a decreasing number of cells with increasing concentrations of the extract ( FIG. 2 ).
  • the number of IC50 obtained for Curcuma mangga Val. et Zipp extract against PC3 cells were 92.60-127.45 ⁇ g/ml.
  • the capability of cell growth inhibition was also seen in A549 cells, with the 1050 obtained between 39.07-42.59 ⁇ g/ml ( FIG. 3 ).
  • the result of FACS experiment showed that after the treatment with the extract of Curcuma mangga Val. et Zipp. there was a change in cell cycle compared to control ( FIG. 4 ).
  • the percentage of GO cycle was increased, meanwhile the cycle of G, S, and G2/M was decreased with increasing concentrations of Curcuma mangga Val. et Zipp. extracts that were given.
  • Curcuma mangga Val. et Zipp. has the capability to inhibit the PC3 cell growth.
  • the capability can be seen from the decreasing number of PC3 cells with increasing concentrations of Curcuma mangga Val. et Zipp. extract that were given. The decrease begun to occur at the concentration of 50 ⁇ g/ml until the concentration of 200 ⁇ g/ml, and the 1050 about 92.60 to 127.45 ⁇ g/ml. Cell growth inhibition processes was also seen in A549 cells. The inhibition started at the concentration of 25 ⁇ g/ml and continues to decrease until the concentration of 75 ⁇ g/ml with 1050 about 39.07 until 42.59 ⁇ g/ml. According to the data that was obtained, it can be seen that Curcuma mangga Val. et Zipp. extract can be used as an inhibitor of PC3 cell growth, as well as inhibitor of A549 cell growth.
  • the result of FACS experiment showed the increasing number of cells at GO phase with increasing concentrations of Curcuma mangga Val. et Zipp. extract that was given.
  • GO phase showed the occurrence of apoptosis and cells death.
  • the increase in the number of cells at the cycle shows the inhibition of PC3 cell growth through the induction of cell death.
  • the result was strengthened by the data that there were decreases in cell cycle G, S, and G2/M with increasing concentrations of Curcuma mangga Val. et Zipp. extract.
  • Those cycles are the signs of cell division activities, thus if those cell cycles were decreasing, it shows a decreasing cell growth (Reynolds & Schecker 1995: 64; Nunez 2001: 67).
  • Curcuma mangga Val. et Zipp. extract to inhibit prostate cancer cells growth, is useful to overcome prostate problem in men, including BPH and prostate cancer.
  • the inhibition of cells growth can stop the velocity of uncontrolled cells growth, meanwhile in BPH, it can reduce the enlargement.
  • This extract also can be developed to inhibit lung cancer cells growth.
  • Curcuma mangga Val. et Zipp. extract has the capability to inhibit the prostate cancer cells growth and to induce PC3 cells death. It can be seen from the decreasing number of cells with increasing concentrations of Curcuma mangga Val. et Zipp. extracts that was given.
  • RNA was isolated from cells after 24 hours treatment using TRIzol reagent. The isolation was performed following the instructions from TRIzol manufacturer. Furthermore, the concentration of the total RNA was calculated using Nano Drop tools based on the isolation results.
  • RNA that was obtained further being a template to do rt-PCR.
  • the DNA that was resulted from rt-PCR subsequently was used as a template to do qPCR.
  • qPCR process was performed using master mix iQ SYBR and specific primers of 5-alpha-reductase-1, androgen receptor, and PI3 kinase. The conditions for qPCR were an optimization results based on the previous experiments.
  • Total protein was isolated after 24 hours treatment with the extract of Curcuma mangga Val. et Zipp. The isolation was performed using Lysis Buffer and TRIzol method. The result of total protein isolation further was calculated using Lowry method. Protein that was obtained subsequently was used as a sample for Western Blot against 5-alpha-reductase and DHT, and the DHT test using Elisa kit Alpha Diagnostic International. The analytical process of semi-Western Blot was performed in accordance to the general method, which is using specific antibody for 5-alpha-reductase-1 and DHT. The detection of Western Blot was performed using HRP-conjugated (Horseradish Peroxidase) secondary antibody and coloring with luminol.
  • qPCR result showed a decreasing 5-alpha-reductase-1 gene expressions, androgen receptor gene, and PI3 kinase gene ( FIGS. 5, 6, and 7 ).
  • the decreasing has started at concentration 50 ⁇ g/ml and continues to decrease until concentration 150 ⁇ g/ml.
  • the Western Blot result showed that the administration of Curcuma mangga Val. et Zipp. extract causes a decreasing protein expression of 5-alpha-reductase-1 ( FIG. 8 ), and consequently the DHT levels was also decreased ( FIG. 9 ).
  • PC3 cells were treated with excessive testosterone to observe the changes in DHT levels.
  • PC3 cells with excessive testosterone showed higher DHT production than the control cells.
  • Cells that were treated with excessive testosterone and Curcuma mangga Val. et Zipp. extract resulted in reduced levels of DHT similar with the cells that were treated with excessive testosterone and finasteride ( FIG. 10 ).
  • 5-alpha-reductase is an enzyme that plays a role in the conversion of androgen testosterone to DHT.
  • One of the functions of the androgen is in the division of prostate cancer cell.
  • 5-alpha-reductase has 2 isozymes: type-1 and type-2. Those two isozymes are different in optimum pH and coding genes. The levels of gene expressions are also different. Type 1 and 2 are more expressed in BPH conditions than a normal, meanwhile in prostate cancer condition, only type-1 that is more expressed than a normal (Smith et al. 1998: 1361; Soderstrom et al. 2001: 855; Schmidt et al. 2004: 944). Since BPH and prostate cancer are the diseases within the scope of this present invention, only 5-alpha-reductase-1 that was used as the parameter.
  • Testosterone will be converted into DHT by 5-alpha-reductase-1 enzyme, which then binding to androgen receptor and activate the regulation of prostate cancer cell growth (Soderstrom et al. 2001: 855; Asada et al. 2001: 2875).
  • the experiment result showed a decreasing gene expression of 5-alpha-reductase-1 in qPCR analysis and decreasing numbers of expressed protein in Western Blot analysis.
  • the decreasing gene expressions and protein numbers showed a decreasing numbers of 5-alpha-reductase-1 in prostate cancer cells after the administration of Curcuma mangga Val. et Zipp. extract.
  • the decreasing number of 5-alpha-reductase-1 enzyme was also supported by the result that DHT level was reduced with increasing concentration of Curcuma mangga Val.
  • et Zipp. extracts that was given.
  • the decreasing number of 5-alpha-reductase-1 enzyme will lead to the decrease in the conversion of testosterone into DHT, thus DHT concentration in prostate cancer cell will be reduced.
  • the decreasing concentration of DHT will cause a decreasing growth regulation of prostate cancer cell due to reduced binding of DHT to the androgen receptor. It can lead to the decreasing growth of prostate cancer cell which is consistent with the previous experiment results (MTT dan FACS).
  • the experiment result also showed a decreasing gene expression of androgen receptor in qPCR analysis, which is showed by the decreasing number of androgen receptors in prostate cancer cells.
  • the previous experiment results showed that the inhibition of prostate cancer cell growth was occurred due to the decreasing concentration of DHT, while this experiment results showed that the inhibition of the cell growth was also occurred due to the inhibition of DHT binding to the androgen receptor.
  • the decreasing number of androgen receptors will also cause a reduced binding of DHT to the receptor, which in the end leads to the decreasing growth regulation of prostate cancer cell.
  • the decreasing gene expressions of 5-alpha-reductase and androgen receptor are related with PI3/Akt pathway.
  • PI3 kinase is an enzyme that plays a role in regulating cellular functions, including in the development of male sexual character and phenotype.
  • the experiment results showed that the treatment of mangga Val. et Zipp. extract in PC3 cells could decrease the numbers of PI3 kinase in mRNA levels.
  • the decrease will affect the regulation of Akt phosphorylation which subsequently affecting the activation of another transcription factors which results in the decreasing transcription of 5-alpha-reductase and androgen receptor.
  • the decreasing expression of those two genes can decrease prostate cancer cell growth.
  • the decreasing gene expression of 5-alpha-reductase-1 and androgen receptor showed the capability of Curcuma mangga Val. et Zipp. extract in treating either BPH or prostate cancer through the inhibition of prostate cancer cell growth.
  • the decrease in 5-alpha-reductase-1 gene expressions will inhibit prostate cancer cells growth through decreasing concentration of DHT required by prostate cancer cells to activate the regulation of prostate cancer cells growth.
  • the decrease in the expressions of androgen receptor inhibited the growth of prostate cancer cells.
  • the decrease in the expressions of those two genes which impact to a decreasing concentration of DHT has caused the inhibition in the regulation of prostate cancer cells growth.
  • RNA total were isolated from the cells after 24 hours treatment using TRIzol reagent. The isolation was performed following the instructions from TRIzol manufacturer. Furthermore, the concentration of the total RNA was calculated using spectrophotometer (Bio Spec Mini, Shimadzu), meanwhile to measure the quality aspects, Agilent Bio Analyzer was used. The RNA was subsequently processed according to the protocol recommended by Affymetrix and Nu Gen. Briefly, a total of 100 ng of RNA total was reverse-transcripted to produce cDNA hybrid that will be used as a template for producing a double-stranded cDNA with a unique DNA/RNA heteroduplex at one end.
  • the amplification process was performed with Single Primer Isothermal Amplification (SPIA) that will produce a single-stranded antisense DNA.
  • SPIA Single Primer Isothermal Amplification
  • cDNA that was resulted from SPIA modification was fragmented and labeled with biotin and was hybridized into Affymetrix Human Gene 1.0 ST Arrays for 18 hours with a temperature 45° C. and 60 rpm rotation.
  • the Arrays were washed and colored according to the FS 4500007 protocol and were scanned using Affymetrix 3000 76 scanner. The data that was obtained, was analyzed using Partek® ExpressTM, thus the changes in gene expressions were known.
  • Microarray results showed that the expression of the genes such as 5-alpha-reductase-1 or 2 and androgen receptor, which are genes related to prostate growth, have decreasing folds (Table 1).
  • GF Epidermal Growth Factor
  • GFR Epidermal Growth Factor Receptor
  • PI3K Phosphoinositide-3-Kinase
  • RAS Phosphoinositide-3-Kinase
  • RAF v-raf murine sarcoma
  • Akt mitogen-activated protein kinase kinase
  • MEK mitogen-activated protein kinase kinase
  • Microarray results have strengthened the indication that the prostate cancer cells growth was inhibited through DHT inhibition pathway. According to the microarray results, the expression of the gene encoding for 5-alpha-reductase-2 (isozyme of 5-alpha-reductase-1) and androgen receptor were decreased. Microarray results also strengthened the indication that the prostate cancer cells growth was inhibited through PI3 kinase and Akt inhibition pathways due to the decrease in the gene expressions of PI3 kinase and Akt. In addition, the gene expressions of MAPK pathways, which are still related to PI3/Akt pathways, were also decreased.
  • et Zipp. extract was also indicated for the Val. et Zipp. extract against genes related to biological oxidation. Meanwhile, based on the 50 down-regulated genes, the majority of the genes that undergo expression changes were in the similar pathways. Several differences were occurred in the genes that were associated with cell cycles, diabetes, cholesterol, as well as lipid and lipoprotein metabolism. Besides its indication for the treatment of prostate disease, Curcuma mangga Val. et Zipp. extract was also indicated for the treatment of other diseases in which its genes are stated in Table 3 and 4.
  • Animals that were used in the present invention were male rats ( Rattus norvegicus ) Wistar strain weighing between 200-250 grams from Indoanilab, Bogor, Indonesia. The animals were bred in special cages, in groups, with a normal light setting, which are 12 hours of light and 12 hours of dark and received food and drinking water ad libitum.
  • the animals were divided into five groups: sham-operated group (normal group), negative control group that is BPH group without any treatment, positive control group that is treated with finasteride 1 mg/kg of body weight, and treatment group which divided into two groups based on the dose of Curcuma mangga Val. et Zipp. extract that they received, namely 92.37 mg/kg and 184.74 mg/kg of body weight. In all animals the growth of its prostate gland were induced, except for the animals in the sham-operated group.
  • Those rats were induced with subcutaneous administration of testosterone injection to stimulate the growth of prostate gland at the dose of 10 mg/kg body weight, every day for 7 days.
  • the administration of testosterone injection was performed after the removal of testes (castration) and sham surgery in rats.
  • the castration procedures were performed to avoid bias caused by the differences of testosterone amount produced by each individual rat.
  • Treatment was given with collapsed dorsal animal position and was prepared according to the operation purposes. Incision was performed in the skin at prepubic area through linea alba. After incisions to the skin and subcutaneous area were performed, then the testis was found. The blood vessel above the testis and vas deferens was fastened using a 4/0 chromic gut. Subsequently, the peritoneal cavity was sutured using a 4/0 chromic gut and the skin was sutured using 4/0 silk.
  • Flunixin was administered subcutaneously twice a day at dose 1.1-2.5 mg/kg of body weight as analgesic, and gentamicin was administered subcutaneously once a day at dose 5-8 mg/kg of body weight, as antibiotic to prevent secondary infections.
  • FIG. 11 is a photo that was taken in the last week from each rat group.
  • Anatomic pathology examination on negative control group found each bladder containing urine in significant amount. It was occurred because prostate that surrounds the vesica urinary, enlarged and clamping the way out of urine. As additional information, prostate is divided into two areas, namely ventral and retral area that surrounds the vesica urinary. Also because of the enlargement, at routine daily examination with palpation at lower abdominal, especially during the third week until the sixth week, it was frequently found hardening due to solids and water fluctuation.
  • FIG. 12 showed a graph of organ weigh of each animal from each treatment, which the prostate size, depends on individual response from each animal, as well. With similar dosage and period of treatment, there were several individuals that significantly have bigger prostate and the others did not have big enough prostate.
  • DHT concentration in rats' plasma can be seen from FIG. 13 . From the graphic, it was known that the administration of testosterone without medical treatment (placebo), resulting in increased levels of DHT. Meanwhile, treatment with finasteride 1 mg/kg and Curcuma mangga Val. et Zipp. extract at doses 92.37 mg/kg and 184.74 mg/kg body weight, can lead to the suppression of DHT plasma concentration.
  • Treatments of patient with prostate gland enlargement can be administered in several mechanisms, including alpha-blocker treatments, anti-androgen medicines, and another types of medicines which works by inhibiting the work of 5-alpha-reductase enzymes in conversion of testosterone into DHT.
  • LH Luteinizing Hormone
  • the present invention includes the pharmaceutical compositions and dosage forms that contains Curcuma mangga Val. et Zipp. extract in effective amount, as an active ingredient in one dosage herb and/or mixed herbs, including carrier, excipients or additives that are pharmaceutically acceptable and physiologically suitable.
  • the active ingredient Curcuma mangga Val. et Zipp. extract can be mixed with, or dissolved in excipient(s), or contained in carrier that can be made in the form of capsule, sachet, paper, as well as other packaging materials. If pharmaceutically acceptable excipient is used as solvent, the excipient can be in form of solid, semi-solid or liquid (oral and injection), that acts as a carrier or medium for the active ingredient.
  • pharmaceutical composition according to this invention can be made in the form of pill, capsule, tablet, powder, sachet, solution, syrup, emulsion, suspension, effervescence tablets, gel, ointment, cream, mouthwash, massage oil, suppository, or injection.
  • pharmaceutical composition comprising Curcuma mangga Val. et Zipp. extract according to this invention can also be made as supplement, vitamin, as well as food and beverage production.
  • composition according to the present invention can be formulated using methods that have been applied in pharmaceutical industry that causes the active ingredient to be released directly, sustained or controlled after the patient receives such dosage forms.
  • Tablet or pill according to the present invention can be coated to extend the half-life of the extract thus its frequency of use can be reduced.
  • Method of formulating this composition in a solid form, such as tablet can be done by mixing the active ingredient of the extract of Curcuma mangga Val. et Zipp., with excipient(s) to form an initial formulation containing homogenous mixture from the composition according to the present invention.
  • the initial formulation is a mixture containing the active ingredient of the Curcuma mangga Val. et Zipp. dispersed homogenously, so it can be uniformly distributed to conform the proper dosage into forms such as, for example, capsule, tablet, or pill.
  • Additional protection coat may be applied to the tablet or pill according to the present invention to reduce or cover the bitter taste from the composition or the active ingredient Curcuma mangga Val. et Zipp. extract.
  • Extract of Curcuma mangga Val. et Zipp. in an effective amount or dosage according to the present invention is the dosage of the extract that can inhibit prostate cancer cells growth.
  • An effective amount depends on the physical condition of the patient, including weight, age, and other factors; includes on type, size and number of prostate cancer cells and other targeted pathologies condition.
  • Liquid dosage forms such as herbal drinks formulation, can be prepared by mixing the active ingredient Curcuma mangga Val. et Zipp. extract with water and surfactant, for example hydroxypropylcellulose or other similar materials.
  • Semi-solid dosage forms such as jelly, can be prepared by mixing the active ingredient Curcuma mangga Val. et Zipp. extract with certain hydrocolloid including gelatin, carrageenan, pectin, gum arabicum, guar gum, and other similar materials.
  • Herbal formulation in solid food preparation can be prepared using the active ingredient Curcuma mangga Val. et Zipp. extract as a component with important effect on body health.
  • the preparation of solid food preparation such as biscuit, bread, and cookies according to this invention can be done using common preparation and other materials including butter, sugar, eggs, and other supporting materials.
  • This invention also anticipated the used of Curcuma mangga Val. et Zipp. extract as a therapy that performed in conjunction with or after radiation therapy.
  • This present invention also anticipated the used of Curcuma mangga Val. et Zipp. extract in conjunction with or as an additional in the composition of anti-BPH or other medical substances that available in market.
  • Extract as well as pharmaceutical composition of Curcuma mangga Val. et Zipp. extract can be made in industrial scale for the production of extract, dry powder extract, and/or pharmaceutical composition, especially for oral dosage forms, either solid, semi-solid, or liquid in its use as drugs of anti-BPH (prostate enlargement) and prostate cancer via Prostate-Growth Reducer Pathway.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
US14/894,615 2013-06-04 2014-06-03 CURCUMA MANGGA VAl ET ZIPP EXTRACT AS A TREATMENT TO OVERCOME PROSTATE PROBLEMS Abandoned US20160143982A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/984,529 US10688146B2 (en) 2013-06-04 2018-05-21 Curcuma mangga val et. zipp. extract as a treatment to overcome prostate problems

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IDP00201300419 2013-06-04
IDP00201300419 2013-06-04
PCT/ID2014/000004 WO2015063751A1 (en) 2013-06-04 2014-06-03 Curcuma mangga val et. zipp. extract as a treatment to overcome prostate problems

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/ID2014/000004 A-371-Of-International WO2015063751A1 (en) 2013-06-04 2014-06-03 Curcuma mangga val et. zipp. extract as a treatment to overcome prostate problems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/984,529 Continuation US10688146B2 (en) 2013-06-04 2018-05-21 Curcuma mangga val et. zipp. extract as a treatment to overcome prostate problems

Publications (1)

Publication Number Publication Date
US20160143982A1 true US20160143982A1 (en) 2016-05-26

Family

ID=53003445

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/894,615 Abandoned US20160143982A1 (en) 2013-06-04 2014-06-03 CURCUMA MANGGA VAl ET ZIPP EXTRACT AS A TREATMENT TO OVERCOME PROSTATE PROBLEMS
US15/984,529 Active US10688146B2 (en) 2013-06-04 2018-05-21 Curcuma mangga val et. zipp. extract as a treatment to overcome prostate problems

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/984,529 Active US10688146B2 (en) 2013-06-04 2018-05-21 Curcuma mangga val et. zipp. extract as a treatment to overcome prostate problems

Country Status (9)

Country Link
US (2) US20160143982A1 (de)
EP (1) EP3003340A4 (de)
JP (1) JP6343339B2 (de)
KR (1) KR102168459B1 (de)
AR (1) AR096464A1 (de)
AU (1) AU2014343198B2 (de)
CA (1) CA2914451C (de)
TW (1) TW201534320A (de)
WO (1) WO2015063751A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3003340A4 (de) * 2013-06-04 2017-01-25 PT. Dexa Medica Curcuma mangga val et. zipp. extrakte als behandlung für prostataprobleme
US20230243810A1 (en) * 2017-02-10 2023-08-03 Academia Sinica Composition and method for modulating fibroblast growth factor receptor 3 activation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630874B (zh) * 2016-02-05 2018-08-01 林岳輝 Method for self-extracting nutrients and nutrients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1045822B1 (de) * 1998-01-09 2003-05-07 Eurovita A/S Bestimmte diterpene, extrakte oder konzentrate von curcuma amada, die diese enthalten zur verwendung als medikamente
US6224877B1 (en) * 1999-09-16 2001-05-01 Council Of Scientific And Industrial Research Process for extraction of curcuminoids from curcuma species
US7390514B2 (en) * 2005-11-28 2008-06-24 Sahajanand Biotech Pvt. Ltd. Herbal composition for treatment and maintenance of hormone dependent conditions, osteoporosis, circulatory conditions, and for use as an immunostimulant
US8394425B2 (en) * 2007-04-05 2013-03-12 Pmc Formulas, Inc. Methods for promoting cellular health and treatment of cancer
KR20120038613A (ko) * 2010-10-14 2012-04-24 주식회사한국전통의학연구소 생약 추출물을 포함하는 폐암 예방 또는 치료용 약학적 조성물
EP3003340A4 (de) * 2013-06-04 2017-01-25 PT. Dexa Medica Curcuma mangga val et. zipp. extrakte als behandlung für prostataprobleme

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3003340A4 (de) * 2013-06-04 2017-01-25 PT. Dexa Medica Curcuma mangga val et. zipp. extrakte als behandlung für prostataprobleme
US20230243810A1 (en) * 2017-02-10 2023-08-03 Academia Sinica Composition and method for modulating fibroblast growth factor receptor 3 activation

Also Published As

Publication number Publication date
CA2914451C (en) 2021-01-19
AU2014343198B2 (en) 2017-06-08
US20180264070A1 (en) 2018-09-20
KR20160016862A (ko) 2016-02-15
AR096464A1 (es) 2015-12-30
WO2015063751A1 (en) 2015-05-07
TW201534320A (zh) 2015-09-16
JP2016524622A (ja) 2016-08-18
CA2914451A1 (en) 2015-05-07
KR102168459B1 (ko) 2020-10-21
EP3003340A1 (de) 2016-04-13
JP6343339B2 (ja) 2018-06-13
US10688146B2 (en) 2020-06-23
EP3003340A4 (de) 2017-01-25
AU2014343198A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
Yang et al. Licorice ethanol extract improves symptoms of polycytic ovary syndrome in Letrozole-induced female rats
TWI454261B (zh) 作為治療劑之色酮類
Chen et al. Tanshinone IIA exerts neuroprotective effects on hippocampus-dependent cognitive impairments in diabetic rats by attenuating ER stress-induced apoptosis
TWI300352B (en) Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract
JP2007513153A (ja) ステロイド／核レセプター媒介性疾患の治療のための組成物および方法
Wang et al. A phytosterol enriched refined extract of Brassica campestris L. pollen significantly improves benign prostatic hyperplasia (BPH) in a rat model as compared to the classical TCM pollen preparation Qianlie Kang Pule’an Tablets
Guo et al. S-petasin induces apoptosis and inhibits cell migration through activation of p53 pathway signaling in melanoma B16F10 cells and A375 cells
US10688146B2 (en) Curcuma mangga val et. zipp. extract as a treatment to overcome prostate problems
Dereli et al. Identification of the main active antidepressant constituents in a traditional Turkish medicinal plant, Centaurea kurdica Reichardt
Kim et al. Corn silk extract improves benign prostatic hyperplasia in experimental rat model
Azubuike et al. Effects of Phyllanthus amarus on epididymal sperm characteristics, testosterone levels and histology of reproductive organs of male rats
Hwangbo et al. A mixture of Morus alba and Angelica keiskei leaf extracts improves muscle atrophy by activating the PI3K/Akt/mTOR signaling pathway and inhibiting FoxO3a in vitro and in vivo
Maniago et al. Angiogenic effect of Curcuma longa Linn.(turmeric) tea powder on the chorioallantoic membrane of 10-day old Annas luzonica (Duck) eggs
JP2012520301A (ja) エストロゲン化合物及びその使用方法
Ibrahim et al. A Brief Review on the Phytochemistry and Pharmacological Activities of Morinda citrifolia L.
Majekodunmi et al. Formulation of acalypha wilkesiana muell. Arg. Ethanol leaf extract into creams for the treatment of microbial skin infections
Lo et al. Benzyl isothiocyanate ameliorates hepatic insulin resistance in mice with high-fat diet-induced nonalcoholic fatty liver disease
KR20190075004A (ko) 데커신 또는 데커시놀 안젤레이트를 유효성분으로 함유하는 복부내장지방 감소용 식품 조성물 또는 약학 조성물
Yang et al. Experiment on the effect of Artemisia sieversiana extract on hair loss prevention and cell growth
RU2571818C2 (ru) Средство (варианты), фармацевтическая композиция и способ химиопрофилактики предрака и рака предстательной железы
Christina et al. Histomorphological changes and alterations in the reproductive parameters of male wistar rats following exposure to ethanolic leaf extract of Datura stramonium (GEGEMU)
KR102309425B1 (ko) 홍삼 오일을 포함하는 전립선 비대증 예방 또는 치료용 약학적 조성물
Agbortai et al. Carbonated Herbal Alcoholic Beverage-Induced Hepatotoxicity in Wistar rats; Role of Aqueous Extracts of Stigma maydis
Muszalska Advancements in the prevention and treatment of benign prostatic hyperplasia, with particular emphasis on fireweed (Epilobium angustifolium L.) and nettle (Urtica dioica L.). A review.
Zhang Would Chinese Herbal Medicines Influence with the Androgen Receptor in Prostate Cancer? Investigations on In Vitro and In Vivo Models

Legal Events

Date Code Title Description
AS Assignment

Owner name: PT DEXA MEDICA, INDONESIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARIPIN, ASEP;KARSONO, AGUNG HERU;MAYASARI, OLIVIA;AND OTHERS;REEL/FRAME:037651/0869

Effective date: 20160122

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION